Sweetgreen (SG): Transaction Recovery Real, But Margin Collapse And Guidance Cut Demand Patience

Sweetgreen shares tumbled after the market closed on August 6, falling around 15% in premarket trading after the company reported a second quarter that contained both a genuine sign of life and a brutal reminder of why this stock has been beaten up. I am maintaining a Hold stance. The sequential improvement in customer transactions is real, but the margin collapse, guidance cut, and lingering food-safety uncertainty mean the risk/reward still favors patience over conviction.

What changed

Revenue came in at $192.7 million, up 3.8% year-over-year and just below Street estimates. That headline growth was entirely driven by new store openings, which contributed $18.4 million and more than offset an $11.2 million decline at comparable restaurants. Comparable sales fell 6.2%, split between a 2.0% drop in transactions and a 4.2% decline in product mix.

The product mix pressure tells the more interesting story. Sweetgreen launched wraps nationally in May as a lower-price handheld entry point to compete with Chipotle and Cava. Wraps reached approximately 20% of menu incidence and helped lift transactions by roughly 500 basis points. But the low entry price dragged product mix and, by extension, margins. Management acknowledged wraps are priced margin-neutral to the rest of the menu, which means they add volume without adding proportionate profitability at current sales volumes.

On the positive side, the transaction trend shows a clear sequential recovery path. Comparable transactions declined 11.2% in Q1, dropped approximately 3% in April and May, and reached roughly flat levels in June. That kind of inflection pattern — from double-digit decline to flat in two months — is the kind of signal that justifies paying attention, even if it's not yet a buy signal.

The margin problem

The quarter's dominant problem is not traffic — it's unit economics. Restaurant-level margin, which measures profit at the store level before corporate overhead, collapsed to 13.1% from 18.9% a year earlier, a compression of 580 basis points. Restaurant-level profit fell $9.9 million to $25.2 million.

Three cost lines all moved against the company:

• Food, beverage, and packaging costs rose to 29.8% of revenue from 27.7%, driven by higher ingredient usage, investments in larger chicken and tofu portions, and promotional activity.
• Labor climbed to 29.2% from 27.5%, reflecting both wage inflation and sales deleverage — when sales fall but labor hours don't drop at the same rate, the labor percentage mechanically rises.
• Other operating expenses (largely utilities and occupancy) rose to 18.5% from 17.0%.

In fast casual, a restaurant-level margin above 20% is the zone where expansion economics make sense — that's roughly where competitors like Cava operate. At 13.1%, Sweetgreen stores are generating enough cash to cover themselves but not enough to justify aggressive expansion or build durable corporate-level profits.

The adjusted EBITDA line — earnings before interest, taxes, depreciation, and amortization, a rough cash-earnings proxy — flipped to a $0.2 million loss from a $6.4 million profit a year ago. At the corporate level, G&A discipline partially offset the store-level deterioration. General and administrative expenses fell to $29.7 million from $34.5 million, driven by lower stock-based compensation and reduced salaries. But the gap between corporate savings and store-level margin destruction is too wide to close.

The cyclospora cloud

Sweetgreen does not use iceberg lettuce, which is the ingredient linked to the multistate cyclospora outbreak that began in mid-July and has sickened thousands across 15 states. But the company has been dragged down by association anyway. Management estimated that cyclospora-related consumer anxiety cost approximately 600 basis points on July comparable sales. A separate jalapeño recall from a supplier — Sweetgreen proactively removed jalapeños from two dressings in affected areas — adds further uncertainty, and management could not yet estimate its impact.

This is not a Sweetgreen food safety failure. It is a category-timing problem. When consumers are anxious about raw produce, the salad-first brand takes heat even when it is innocent. The question is duration. The CDC outbreak investigation is still active, with additional states and cases being added as of early August. Sweetgreen's guidance now bakes in a worst-case assumption for the rest of the year. If consumer confidence rebounds quickly in Q3, the guidance could look overly conservative and the stock could bounce. If the anxiety lingers through the fall back-to-school season, the headwind extends.

The guidance cut

The full-year outlook was revised sharply lower:

• Comparable sales: −7% to −8% (prior guidance: −2% to −4%)
• Restaurant-level margin: 10.5%–11.0% (prior guidance: 14.2%–14.7%)
• Adjusted EBITDA: (−$27M) to (−$23M) (prior guidance: $1M–$6M)

The prior guidance already assumed a difficult year — the −2% to −4% comp outlook set in October 2025 was a concession to slowing demand. The new guidance pushes the company into meaningful cash burn territory. The balance sheet can absorb it: Sweetgreen held $142.6 million in cash as of June 28, and the net loss for Q2 was $26.3 million. But a full-year adjusted EBITDA in the range of negative $23 million to negative $27 million means the company is burning cash at a rate that eats into its war chest even before capex for new stores and corporate overhead.

Valuation and the price of fear

Sweetgreen's stock is down approximately 86% from its peak in late 2024, and the post-earnings selloff pushed it to around $5.80–$6.00. The market cap sits near $650 million. The price-to-sales ratio is roughly 1.0x on annualized revenue.

In isolation, a 1x revenue multiple on a brand with 287 locations and a recognizable name looks distressed. The market is pricing this as a company in terminal decline. That is too extreme. But it is also not a bargain unless the operating metrics turn. A cheap multiple without a growth or margin path is just cheap — not a buy.

The case for patience rests on three observable signals. First, the transaction recovery trajectory from −11.2% to flat in three months is the strongest data point in the company's favor. Second, wraps are a legitimate product answer to the handheld competition, and their 50%+ 30-day return rate suggests they are building habits, not just discounting one-time visits. Third, the "Create Your Own" pricing test, which bundles protein into the base price, is rolling out from Indianapolis to D.C. and Southern California — if it lifts average ticket without killing margin, it addresses both the mix and traffic problems simultaneously.

But none of these signals is priced into the current guidance. The −7% to −8% comp outlook and 10.5%–11% restaurant margin guidance represent a business that is still shrinking and barely covering its store-level costs. The catalyst clock for a valuation re-rating requires at least one quarter showing positive comps and margin above 15%, and there is no reason to expect that before Q4 2026 at the earliest.

Risks

• The cyclospora cloud could extend into fall if the CDC investigation expands or if additional food safety scares hit the produce supply chain.
• Wraps may continue to drag product mix if low-price entry converts to habitual low-ticket visits rather than upselling to higher-margin items.
• A restaurant-level margin near 10.5% at full year leaves virtually no operating leverage for corporate-level profitability, keeping the company in net cash-burn territory.
• Sweetgreen has not raised menu prices in over a year, and its price increases have trailed industry inflation by more than 13 percentage points since 2019. Repricing is possible but carries risk of further transaction loss in an already sensitive demand environment.

Investor takeaway

I am maintaining a Hold. The stock has sold off enough to reflect a lot of bad news, including a food safety scare Sweetgreen didn't cause. The transaction recovery is the real signal underneath the noise. But the margin collapse and guidance cut move the proof point too far out to justify a buy.

I would need to see Q3 comps return to positive territory, restaurant-level margin back above 15%, and a revised full-year outlook that puts adjusted EBITDA back in positive territory before changing my stance. The next earnings report, expected in early November, will be the first real test of whether the cyclospora headwind clears and the transaction recovery sustains. Until then, the valuation is cheap but the operating path is unproven — and that combination is not a reason to buy, it is a reason to watch.

Rating: Hold